Electrochemical sensing of sildenafil in pharmaceutical formulations using an (S,N)-doped reduced graphene oxide-modified electrode
Abstract
In this work, (S,N)-co-doped reduced graphene oxide ((S,N)-rGO) was successfully synthesized via thermal treatment and thoroughly characterized by X-ray diffraction, high-resolution transmission electron microscopy, elemental mapping, photoluminescence, and Raman spectroscopy, confirming the successful incorporation of nitrogen and sulfur into the graphene framework. The obtained (S,N)-rGO was used to modify a glassy carbon electrode for the electrochemical determination of sildenafil (SDN). The modified electrode exhibited enhanced electrocatalytic activity toward SDN oxidation, providing a well-defined current response. Under optimized conditions, the sensor showed a good linear relationship between peak current and SDN concentration in the range of 0.25-4.98 µM, with a low limit of detection of 0.24 µM and a limit of quantification of 0.78 µM. The proposed sensor demonstrated satisfactory repeatability, reproducibility, and stability, as well as good selectivity in the presence of potential interfering substances. The applicability of the method was validated by the determination of SDN in pharmaceutical samples. The results were in good agreement with those from high-performance liquid chromatography, indicating that the proposed electrochemical method is reliable and suitable for practical analysis.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.